Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ji Hu

Showing results (421-430 of 428) with videos related to

Pageof 43
Sort By:
You have reached the last page of results.This site can display upto 428 results.
Journal of Medicinal Chemistry|June 28, 2016
Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase InhibitorJorge Garcia Fortanet, Christine Hiu-Tung Chen, Ying-Nan P Chen, et al.
Journal of Orthopaedic Translation|May 25, 2026
Efficacy of once-weekly teriparatide versus alendronate in Chinese postmenopausal osteoporosis: a randomised, open-label, active-controlled, 48-week, multicentre phase III studyJiemei Gu, Aijun Chao, Yanan Huo, et al.
Cell|April 3, 2025
Therapeutic potential of allosteric HECT E3 ligase inhibitionAlexander M K Rothman, Amir Florentin, Florence Zink, et al.
Diabetes Care|June 2, 2019
Identification of Novel T1D Risk Loci and Their Association With Age and Islet Function at Diagnosis in Autoantibody-Positive T1D Individuals: Based on a Two-Stage Genome-Wide Association StudyMeng Zhu, Kuanfeng Xu, Yang Chen, et al.
Nature|July 1, 2016
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinasesYing-Nan P Chen, Matthew J LaMarche, Ho Man Chan, et al.
Nature Chemical Biology|September 6, 2016
Small-molecule WNK inhibition regulates cardiovascular and renal functionKen Yamada, Hyi-Man Park, Dean F Rigel, et al.
Journal of Medicinal Chemistry|September 10, 2020
Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of CancerMatthew J LaMarche, Michael Acker, Andreea Argintaru, et al.
Science China. Life Sciences|May 27, 2016
The heterogeneity of islet autoantibodies and the progression of islet failure in type 1 diabetic patientsJin Liu, Lingling Bian, Li Ji, et al.
Pageof 43

Showing results (421-430 of 428) with videos related to

Sort By:
Pageof 43
You have reached the last page of results.This site can display upto 428 results.
Journal of Medicinal Chemistry|June 28, 2016
Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase InhibitorJorge Garcia Fortanet, Christine Hiu-Tung Chen, Ying-Nan P Chen, et al.
Journal of Orthopaedic Translation|May 25, 2026
Efficacy of once-weekly teriparatide versus alendronate in Chinese postmenopausal osteoporosis: a randomised, open-label, active-controlled, 48-week, multicentre phase III studyJiemei Gu, Aijun Chao, Yanan Huo, et al.
Cell|April 3, 2025
Therapeutic potential of allosteric HECT E3 ligase inhibitionAlexander M K Rothman, Amir Florentin, Florence Zink, et al.
Diabetes Care|June 2, 2019
Identification of Novel T1D Risk Loci and Their Association With Age and Islet Function at Diagnosis in Autoantibody-Positive T1D Individuals: Based on a Two-Stage Genome-Wide Association StudyMeng Zhu, Kuanfeng Xu, Yang Chen, et al.
Nature|July 1, 2016
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinasesYing-Nan P Chen, Matthew J LaMarche, Ho Man Chan, et al.
Nature Chemical Biology|September 6, 2016
Small-molecule WNK inhibition regulates cardiovascular and renal functionKen Yamada, Hyi-Man Park, Dean F Rigel, et al.
Journal of Medicinal Chemistry|September 10, 2020
Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of CancerMatthew J LaMarche, Michael Acker, Andreea Argintaru, et al.
Science China. Life Sciences|May 27, 2016
The heterogeneity of islet autoantibodies and the progression of islet failure in type 1 diabetic patientsJin Liu, Lingling Bian, Li Ji, et al.
Pageof 43